BEAMBeam Therapeutics Inc.

1. Aug 4, 2026Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)Earnings release · press release
2. May 7, 2026Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
3. Mar 5, 2026Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kobe University On March 2, 2026 (the “Termination Date”), Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio …Material agreement terminated · Form 8-K
4. Feb 24, 2026On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative …Material agreement entered · Form 8-K
5. Feb 12, 2026As previously reported, Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) are parties to a License Agreement dated March 27, 2019 (the “Bio Palette-Beam License”), pursuant to which the Company has sublicensed from Bio Palette certain patents (the “Patents”) that Bio Palette licensed …Material agreement entered · Form 8-K
6. Feb 5, 2026On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the “Company”) with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026.Director or officer change · Form 8-K
7. Jan 12, 2026Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition.Earnings release · press release
8. Dec 11, 2025On December 8, 2025, Bristol-Myers Squibb Company (“BMS”) completed its previously announced acquisition of Orbital Therapeutics, Inc. (“Orbital”) pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS (the “Acquisition”)Acquisition or disposition completed · Form 8-K
9. Nov 4, 2025Beam Therapeutics Reports Third Quarter 2025 Financial Results and.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.